Lattice radiation combined with immunotherapy for advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase II trial gives lattice radiation therapy (LRT) to the largest tumor by placing 0.5–3 cm high-dose spheres within the gross tumor volume while delivering low-dose radiation to other metastases, followed by immunotherapy given during or within one week after radiotherapy. LRT targets are spaced 2.0–5.0 cm apart, sized to 1–10% of the GTV, and planned to avoid blood vessels and minimize dose to organs at risk, with single-lesion D95 goals of ≥1 Gy/fraction for the GTV and 8–12 Gy/fraction for LRT targets. Other irradiated metastases receive 100–300 cGy × 5 fractions, and brain or bone metastases may receive palliative radiotherapy per routine care. The trial will track treatment-related toxicities, immune-related adverse events, radiographic responses, and exploratory biomarker changes.

Why it matters

Who can join: the full rules

\*\*Inclusion Criteria:\*\*

1. Signed informed consent.
2. Histologically or cytologically confirmed malignant solid tumor.
3. Advanced solid tumor unsuitable for surgery as determined by a multidisciplinary tumor board or consulting physicians.
4. No available standard therapy or inability to tolerate it, with imaging and clinical assessment showing stable disease (SD) or progressive disease (PD).
5. Age ≥18 years on the day of signing informed consent.
6. No prior radiotherapy to the proposed site, or last radiotherapy ≥6 months ago.
7. KPS score ≥70.
8. At least one measurable lesion per RECIST 1.1. Previously irradiated lesions qualify only if significant progression post - radiotherapy.
9. Life expectancy \>3 months.
10. Adequate organ and bone marrow function:

    * Marrow: ANC ≥1.5×10⁹/L, platelets ≥80×10⁹/L, hemoglobin ≥9 g/dL;
    * Liver: Total bilirubin ≤1.5× upper limit of normal (ULN), ALT/AST ≤1.5× ULN;
    * Kidney: Serum creatinine ≤1.5× ULN or creatinine clearance ≥50 ml/min, blood urea nitrogen ≤200 mg/L;
    * Coagulation: INR ≤1.5× ULN, PTT ≤1.5× ULN.
11. Recovery from prior therapy - related adverse events (≤Grade 1 or baseline).
12. Willingness to use appropriate contraception.
13. No radiotherapy contraindications as judged by the radiation oncologist.
14. Agreement to receive both immunotherapy and radiotherapy.

\*\*Exclusion Criteria:\*\*

1. Active central nervous system (CNS) metastases, carcinomatous meningitis, or spinal cord compression.
2. Severe comorbidities such as myocardial infarction within 6 months, severe arrhythmias, or psychosis that may affect treatment completion or result in a life expectancy of \<3 months.
3. Evidence of interstitial lung disease or active/non - infectious pneumonia (e.g., drug - induced, radiation - induced) requiring steroid treatment.
4. History of pulmonary fibrosis, pulmonary artery hypertension, or severe irreversible airway obstruction.
5. Presence of peripheral neuropathy.
6. Severe organ dysfunction (e.g., hepatic, cardiopulmonary failure) that is likely to make radiotherapy intolerable.
7. Known allergy to study drugs or excipients, or a history of severe allergic reaction to any PD - 1 monoclonal antibody.
8. Serious infection within 4 weeks prior to the start of study treatment, including but not limited to hospitalization for infection, bacteremia, or severe pneumonia; or receipt of oral or intravenous antibiotics within 2 weeks prior to study treatment. Patients receiving prophylactic antibiotics (e.g., for urinary tract infections or chronic obstructive pulmonary disease exacerbations) are eligible.
9. Known or suspected active autoimmune disease (e.g., uveitis, colitis, hepatitis, hypophysitis, vasculitis, nephritis, thyroiditis). Exceptions: patients with vitiligo, cured childhood asthma; patients with well - controlled type 1 diabetes on insulin.
10. History of allogeneic organ transplant (except corneal) or allogeneic hematopoietic stem cell transplant.
11. Pregnant or breastfeeding women.
12. Any other condition that the investigator deems a valid reason for disqualification based on the protocol.

Where it's running

• Beijing Friendship Hospital, Capital Medical University
  Beijing, Beijing Municipality, China Recruiting
• Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine
  Cangzhou, Hebei, China Recruiting
• Tianjin Medical University Cancer Institute & Hospital
  Tianjin, Tianjin Municipality, China Recruiting

Study contacts

• Study coordinator: Ningbo Liu, Doctor
• Email: liuningbo@tjmuch.com
• Phone: +8615602036608

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining advanced radiotherapy with immune therapy for lung cancer

  This study is testing a new treatment for advanced lung cancer that combines special radiation therapy with immune therapy to see if it can help patients feel better and improve their outcomes.

  Recruiting Xinqiao Hospital of Chongqing · Chongqing, Chongqing Municipality and 1 other locations · NCT05754203

• Intestinal Low-Dose Radiotherapy plus Immunochemotherapy to Convert Borderline Resectable or Unresectable Esophageal Squamous Cell Carcinoma

  This study tests whether adding a very low dose intestinal radiotherapy with immunochemotherapy can make advanced esophageal squamous cell carcinoma operable for patients who can’t be surgically removed today.

  Recruiting Phase 2 Shantou University Medical College · Shantou, Guangdong · NCT07339488

• PRaG-1 Plus PRaG Therapy with Radiation and Immunotherapy in Older Adults with Advanced Solid Tumors

  This study tests whether giving PRaG-1 Cordycepin tablets together with radiation, immune-boosting injections, and PD-1/PD-L1 inhibitors can help people aged 65 and older with advanced solid tumors.

  Recruiting Phase 2 Second Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07267234

• Multimodal radiotherapy for advanced renal cell carcinoma after immunotherapy

  This study is testing whether combining different types of radiation therapy with ongoing treatment can help people with advanced kidney cancer who haven't responded well to previous immunotherapy.

  Recruiting Phase 2 Jinling Hospital, China · Nanjing, Jiangsu · NCT06255223

• Assessing safety of combining radiotherapy with new systemic therapies for breast cancer

  This study is testing if it's safe to give new breast cancer treatments together with radiation therapy to see if they can work well together for patients who need both.

  Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT06197581

• Evaluating COVID-19 vaccine effectiveness in lung cancer patients

  This study is testing whether getting a COVID-19 booster shot helps lung cancer patients on treatment avoid severe infections and stay healthier compared to those who don’t get the booster.

  Recruiting Peking Union Medical College Hospital · Beijing · NCT06168032

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.